{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 3.1 Study', 'Ongoing FTIH study number has', 'Editorial changes', 'Rationale', 'been changed from BMA117158 to', 'BMA117159', 'Section 3.4.2 Corneal', 'Additional information regarding', 'Events', 'corneal toxicity included', 'Included new section', 'To support the additional arm', 'Section 3.4.3', 'Pharmacokinetics', '\"Pharmacokinetics; with section', 'that includes dose level 2.5mg/kg', 'number 3.4.3', 'Updated to reflect the change in', 'Section 3.5.3 Overall', 'Overall Benefit-Risk conclusions is', 'study design.', 'Benefit- Risk', 'Conclusions', 'updated to reflect the additional', 'dose.', 'Section 4 Objectives', 'Primary objective has been modified:', 'Updated to reflect the change in', 'and Endpoints,', 'to evaluate the clinical efficacy of 2', 'study design.', 'Primary Objective', 'doses of GSK2857916 in', 'participants with relapsed/refractory', 'multiple myeloma by overall', 'response rate', 'To gain clinical experience with', 'Exploratory Objective', 'the lyophilized configuration.', 'New exploratory endpoint has been', 'included: To assess the safety,', 'efficacy, immunogenicity, and', 'pharmacokinetics of GSK2857916 in', 'a lyophilized configuration (n=25)', 'Number increased to reflect the', 'additional arm and increased', 'Ocular Sub-Study', 'Objective', 'study sample size.', 'Number of participants to evaluate', 'the effect of topical corticosteroids', 'on corneal findings has been', 'increased to 30 (15 in each dose', 'arm).', 'Section 5 Study', 'Study design description and the', 'Language and the schema', 'Design', 'Study Schema revised.', 'modified to clarify changes in', 'study design have been added,', 'including the addition of a second', 'Efficacy and safety results from the', 'arm, change to the total number', 'interim analysis will not be shared', 'of participants, IA to assess', 'with investigators or other study/site', 'futility, IDMC to review IA results,', 'personnel', 'and an additional cohort of', 'participants (n=25) who will', 'receive the lyophilized', 'configuration.', '146']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 5.2 Number of', 'Number of participants to be', 'Study design has changed from 1', 'Participants', 'screened has been changed from', 'arm to 2 arms, thus the sample', '100 to 170, to be enrolled changed', 'size is increased. Ocular sub-', 'from 90 to 155 and number of', 'study sample size is increased', 'recruitment centers changed from 30', 'for same reason.', 'to 60 investigational sites. Number of', 'participants in the ocular sub-study', 'increased to 30', 'Section 5.3 Participant', 'Definition of the study-completed', 'Language to offer participants', 'and Study Completion', 'participant has been modified', 'this option was inadvertently', 'omitted.', 'New criteria have been added: If a', 'participant remains on treatment at', 'the time end of study is achieved,', 'they will be offered an option to', 'extend treatment on this or another', 'protocol.', 'Section 5.4: Scientific', 'Scientific rationale and dose', 'Scientific rationale and dose', 'Rationale of Study', 'justification sections are updated.', 'justification updated to address', 'Design', 'new design and additional dose', 'level.', 'Section 5.5: Dose', 'Justification', 'Section 6.2 Exclusion', 'Deletion of exclusion criterion #3', '#3 Per regulatory agency', 'Criteria', 'regarding best corrected visual', 'suggestion, the criterion related', 'acuity', 'to visual acuity limitations', 'New #2 Exclusion criteria for', 'deleted. Requirement for', 'symptomatic amyloidosis, active', 'preexisting conditions has been', '\"polyneuropathy, organomegaly,', 'revised according to feedback for', 'endocrinopathy, myeloma protein,', 'regulatory agencies.', \"and skin changes' (POEMS)\", 'New # 2 Included to avoid', 'syndrome, active plasma cell', 'unpredictable toxicity.', 'leukemia at the time of screening', 'and Prior allogeneic stem cell', 'transplant has been added.', 'Section 7 Treatments', 'Table listing the study treatments.', 'To provide details of how the', 'lower dosage form and the', 'lyophilized form are supplied to', 'the sites.', '147']\n\n###\n\n", "completion": "END"}